Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.
Ceftazidime was administered intravenously or intramuscularly or both in doses of 1 to 6 g per day to 33 patients with serious gram-negative bacillary infections (12 pulmonary, 10 urinary tract, 4 soft tissue, 4 intraabdominal, and 3 miscellaneous infections). Twenty-one patients were septicemic. We...
Sparad:
| I publikationen: | Antimicrob Agents Chemother |
|---|---|
| Huvudupphov: | , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
American Society for Microbiology (ASM)
1983
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC185133/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6357068/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.24.2.176 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|